Keywords
Last Name
Institution

Sondra Berger

Title
InstitutionMedical University of South Carolina
DepartmentSCCP Pharmaceutical and Biomedical Sciences - USC Campus
Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. El-Mesallamy HO, El Magdoub HM, Chapman JM, Hamdy NM, Schaalan MF, Hammad LN, Berger SH. Biomolecular study of human thymidylate synthase conformer-selective inhibitors: New chemotherapeutic approach. PLoS One. 2018; 13(3):e0193810. PMID: 29538414.
      View in: PubMed
    2. Luo B, Johnson SR, Lebioda L, Berger SH. Evolution of metamorphism in thymidylate synthases within the primate lineages. J Mol Evol. 2011 Mar; 72(3):306-14. PMID: 21318388.
      View in: PubMed
    3. Luo B, Repalli J, Yousef AM, Johnson SR, Lebioda L, Berger SH. Human thymidylate synthase with loop 181-197 stabilized in an inactive conformation: ligand interactions, phosphorylation, and inhibition profiles. Protein Sci. 2011 Jan; 20(1):87-94. PMID: 21064161.
      View in: PubMed
    4. Huang X, Gibson LM, Bell BJ, Lovelace LL, Peña MM, Berger FG, Berger SH, Lebioda L. Replacement of Val3 in human thymidylate synthase affects its kinetic properties and intracellular stability . Biochemistry. 2010 Mar 23; 49(11):2475-82. PMID: 20151707.
      View in: PubMed
    5. Lovelace LL, Johnson SR, Gibson LM, Bell BJ, Berger SH, Lebioda L. Variants of human thymidylate synthase with loop 181-197 stabilized in the inactive conformation. Protein Sci. 2009 Aug; 18(8):1628-36. PMID: 19569192.
      View in: PubMed
    6. Berger SH, Pittman DL, Wyatt MD. Uracil in DNA: consequences for carcinogenesis and chemotherapy. Biochem Pharmacol. 2008 Sep 15; 76(6):697-706. PMID: 18599024.
      View in: PubMed
    7. Berger FG, Berger SH. Thymidylate synthase as a chemotherapeutic drug target: where are we after fifty years? Cancer Biol Ther. 2006 Sep; 5(9):1238-41. PMID: 17035726.
      View in: PubMed
    8. Adams SA, Hebert JR, Bolick-Aldrich S, Daguise VG, Mosley CM, Modayil MV, Berger SH, Teas J, Mitas M, Cunningham JE, Steck SE, Burch J, Butler WM, Horner MJ, Brandt HM. Breast cancer disparities in South Carolina: early detection, special programs, and descriptive epidemiology. J S C Med Assoc. 2006 Aug; 102(7):231-9. PMID: 17319236.
      View in: PubMed
    9. You S, Ohmori M, Peña MM, Nassri B, Quiton J, Al-Assad ZA, Liu L, Wood PA, Berger SH, Liu Z, Wyatt MD, Price RL, Berger FG, Hrushesky WJ. Developmental abnormalities in multiple proliferative tissues of Apc(Min/+) mice. Int J Exp Pathol. 2006 Jun; 87(3):227-36. PMID: 16709231.
      View in: PubMed
    10. Li L, Connor EE, Berger SH, Wyatt MD. Determination of apoptosis, uracil incorporation, DNA strand breaks, and sister chromatid exchanges under conditions of thymidylate deprivation in a model of BER deficiency. Biochem Pharmacol. 2005 Nov 15; 70(10):1458-68. PMID: 16191427.
      View in: PubMed
    11. Li L, Berger SH, Wyatt MD. Involvement of base excision repair in response to therapy targeted at thymidylate synthase. Mol Cancer Ther. 2004 Jun; 3(6):747-53. PMID: 15210861.
      View in: PubMed
    12. Berger SH, Berger FG, Lebioda L. Effects of ligand binding and conformational switching on intracellular stability of human thymidylate synthase. Biochim Biophys Acta. 2004 Jan 14; 1696(1):15-22. PMID: 14726200.
      View in: PubMed
    Berger's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description